ライフサイエンスコーパス: oxaliplatin

1 pretreatment sensitized HCT116-OxR cells to oxaliplatin.

2 axel and with beneficial effects extended to oxaliplatin.

3 ent with the clinically used anticancer drug oxaliplatin.

4 ged a cumulative dose of 1,426 +/- 204 mg/m2 oxaliplatin.

5 tients receiving i.v. mangafodipir following oxaliplatin.

6 nts received an average of 880 +/- 239 mg/m2 oxaliplatin.

7 leucovorin and fluorouracil with or without oxaliplatin.

8 djuvant chemotherapy with 5-fluorouracil and oxaliplatin.

9 umour), and previous adjuvant treatment with oxaliplatin.

10 re examined in mice following treatment with oxaliplatin.

11 d to be worse in patients receiving adjuvant oxaliplatin.

12 or between the two regimens with or without oxaliplatin.

13 sting before and then prior to each cycle of oxaliplatin.

14 ith selected chemotherapeutic agents such as oxaliplatin.

15 ath responses of CRC cells to 5-fluorouracil/oxaliplatin.

16 e lower extremities among those treated with oxaliplatin.

17 with those treated with chemotherapy without oxaliplatin.

18 th the clinical platinum drugs cisplatin and oxaliplatin.

19 n patients with mCRC previously treated with oxaliplatin.

20 -risk stage II patients did not benefit from oxaliplatin.

21 t show significant differences between 1 and oxaliplatin.

22 stance to fluorouracil but not irinotecan or oxaliplatin.

23 g factors for curative cancer treatment with oxaliplatin.

24 the neuropathic hypersensitivity induced by oxaliplatin.

25 ith 5-fluorouracil (3.1, 31, or 310 muM) and oxaliplatin (0.7 or 7 muM) or radiation (2 or 4.5 Gy).

26 nitumumab (mEOC+P; epirubicin 50 mg/m(2) and oxaliplatin 100 mg/m(2) on day 1, capecitabine 1000 mg/m

27 ay GEMOX regimen (gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 Day 1, every 2 weeks), and 20 pati

28 m(2) repeated every 2 weeks (regimen one) or oxaliplatin 130 mg/m(2) intravenously over 2 h and oral

29 were randomly assigned to receive XELOX, as oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1,000

30 of open-label EOC (epirubicin 50 mg/m(2) and oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1250 m

31 er 3 h on day 1) before BEP plus intravenous oxaliplatin (130 mg/m(2) over 3 h on day 10; two cycles)

32 d modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400

33 axons showed that cooling in the presence of oxaliplatin (30-100 muM; 90 min) induced bursts of actio

34 mg/kg), the third irinotecan (80 mg/kg) plus oxaliplatin (5 mg/kg), and the fourth vehicle (0.9% NaCl

35 was given irinotecan (100 mg/kg), the second oxaliplatin (5 mg/kg), the third irinotecan (80 mg/kg) p

36 d with biweekly, intraarterial chemotherapy (oxaliplatin, 5-Flourouracil, folinic acid).

37 0003594), in which different combinations of oxaliplatin, 5-fluorouracil, and irinotecan were investi

38 mg/m(2) twice daily on days 1-14 and 22-35), oxaliplatin (50 mg/m(2) on weeks 1, 2, 4, and 5), and ra

39 days per week), with or without intravenous oxaliplatin (50 mg/m(2) once per week for 5 weeks) or or

40 e per day, 5 days per week), with or without oxaliplatin (50 mg/m(2) once per week for 5 weeks).

41 on-CRC = 37), Oxaliplatin (n = 10) (CRC), or Oxaliplatin + 5FU (n = 12) (CRC).

42 1000 mg/m intravenously over 100 minutes and oxaliplatin 80 mg/m intravenously over 2 hours, every 2

43 the discretion of the treating investigator, oxaliplatin 85 mg/m(2) in a 2-h infusion, bolus fluorour

44 Chemotherapy consisted of oxaliplatin 85 mg/m(2) intravenously over 2 h and fluoro

45 llocated to receive either FOLFIRINOX alone (oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovor

46 2:1) to preoperative (three cycles of OxMdG [oxaliplatin 85 mg/m(2), l-folinic acid 175 mg, fluoroura

47 ere randomly assigned to receive FOLFIRINOX (oxaliplatin, 85 mg/m(2); irinotecan, 180 mg/m(2); leucov

48 2206 135 mg orally once per week or mFOLFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 240

49 Oxaliplatin, a commonly used chemotherapeutic agent, is

50 travenous calcium/magnesium before and after oxaliplatin, a placebo before and after, or calcium/magn

51 The impact of oxaliplatin added to FU + LV on the time course of recur

52 nter trial to evaluate the benefit of FU and oxaliplatin administered as modified FOLFOX6 (mFOLFOX6;

53 We evaluated the efficacy of gemcitabine and oxaliplatin administered as preoperative therapy in pati

54 No benefit was observed with the addition of oxaliplatin, administered as mFOLFOX6, versus infusional

55 Oxaliplatin also significantly reduced risk of death fro

56 Here we focus on oxaliplatin, an immunogenic chemotherapeutic agent that

57 two methyl-substituted enantiomerically pure oxaliplatin analogs [[(1R,2R,4R)-4-methyl-1,2-cyclohexan

58 Although the novel oxaliplatin analogs demonstrated in multiple aspects act

59 To summarize, methyl-substituted oxaliplatin analogs harbor improved therapeutic characte

60 nd markedly enhances PDA cell sensitivity to oxaliplatin and 5-fluorouracil under physiologic low oxy

61 oard meeting, and adjuvant chemotherapy with oxaliplatin and capecitabine was recommended.

62 gimens included in our analyses were: XELOX (oxaliplatin and capecitabine); leucovorin and fluorourac

63 rectal cancer invasiveness and resistance to oxaliplatin and cisplatin both in vitro and in vivo.

64 which lack functional Na(V)1.6, no effect of oxaliplatin and cooling was observed.

65 ned to folinic acid and fluorouracil (FF) or oxaliplatin and FF (OFF).

66 survival, a significant interaction between oxaliplatin and fluoropyrimidine was recorded in the mul

67 e survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy.

68 ultaneous delivery of two chemotherapeutics, oxaliplatin and gemcitabine monophosphate (GMP), at 30 w

69 g, fluorouracil, leucovorin, irinotecan, and oxaliplatin and gemcitabine plus nanoparticle albumin-bo

70 A strong synergistic therapeutic effect of oxaliplatin and GMP was observed in vitro against AsPc-1

71 in combination with FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluoroura

72 with poor prognosis, and were refractory to oxaliplatin and irinotecan.

73 red between the capecitabine with or without oxaliplatin and leucovorin and fluorouracil with or with

74 In 77% of patients treated with oxaliplatin and mangafodipir, neuropathy improved or sta

75 effects were monitored for up to 8 cycles of oxaliplatin and mangafodipir.

76 Synergy between oxaliplatin and pyrolipid-induced PDT kills tumour cells

77 ultraviolet (UV) and the UV mimetic compound oxaliplatin and the radiomimetic compound doxorubicin pr

78 ps who received capecitabine with or without oxaliplatin and those who received leucovorin and fluoro

79 XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time cours

80 tases between 1998 and 2011 and treated with oxaliplatin and/or irinotecan-based preoperative chemoth

81 , folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nanoparticle albumin-b

82 ine; FOLFOX-4 (leucovorin, fluorouracil, and oxaliplatin); and modified FOLFOX-6 (mFOLFOX-6).

83 (66%) had received at least 6 cycles of HAI oxaliplatin, and 22 patients (50%) had received the full

84 r after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

85 th a first-line combination regimen of 5-FU, oxaliplatin, and bevacizumab (FOLFOX-bevacizumab), as co

86 nti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with adv

87 perative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed by surgery an

88 istische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phas

89 chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) showed superior

90 The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-

91 e premise that more aggressive intervention (oxaliplatin- and irinotecan-based chemotherapy and/or su

92 all survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil

93 e platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a c

94 num-based drugs (cisplatin, carboplatin, and oxaliplatin) are widely used therapeutic agents for canc

95 in and its platinum analogs, carboplatin and oxaliplatin, are some of the most widely used cancer che

96 as fluorouracil, leucovorin, irinotecan, and oxaliplatin as well as gemcitabine/nab-paclitaxel are ac

97 613 in combination with modified FOLFIRINOX (oxaliplatin at 65 mg/m(2), leucovorin at 400 mg/m(2), ir

98 y and open intraperitoneal chemotherapy with oxaliplatin at a constant concentration (150 mg/L) for 3

99 Notably, CRLX101 was more effective than oxaliplatin at enhancing the efficacy of chemoradiothera

100 The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over

101 Oxaliplatin-based adjuvant therapy is the standard of ca

102 ation were randomly assigned (1:1) to either oxaliplatin-based chemotherapy (FOLFOX: leucovorin, fluo

103 All patients had irinotecan and/or oxaliplatin-based chemotherapy before liver surgery.

104 the association of sinusoidal dilatation and oxaliplatin-based chemotherapy but not for estroprogesta

105 In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically

106 s of colorectal cancer patients treated with oxaliplatin-based chemotherapy.

107 er, who were not deemed to be candidates for oxaliplatin-based or irinotecan-based chemotherapy regim

108 ive neurotoxicity is a prominent toxicity of oxaliplatin-based therapy.

109 r cells, which was accompanied by changes in oxaliplatin but not cisplatin cytotoxicity.

110 ion levels could predict cell sensitivity to oxaliplatin but not cisplatin.

111 fibers by light elicits pain behavior in the oxaliplatin but not the CCI model.

112 sistant clones exhibit cross-resistance with oxaliplatin but not with ionising radiation or 5-fluorur

113 ropathic pain evoked by the chemotherapeutic oxaliplatin, but not in the chronic constriction injury

114 ensitivity to several antineoplastic agents (oxaliplatin, carboplatin, paclitaxel, docetaxel, cycloph

115 Among other substances, oxaliplatin causes CIPN in up to 80% of treated patients

116 otherapy, and the use of combined irinotecan/oxaliplatin chemotherapy were more frequent in the RM gr

117 s revealed specific morphological effects of oxaliplatin chemotherapy, radiotherapy, and photodynamic

118 acid [leucovorin calcium], fluorouracil, and oxaliplatin) chemotherapy with or without cetuximab (Nor

119 DNA-damaging anticancer agents (mitomycin C, oxaliplatin, cisplatin, carboplatin, and a PARP inhibito

120 ropriately selected immunogenic drugs (e.g., oxaliplatin combined with cyclophosphamide for treatment

121 Oxaliplatin combined with fluoropyrimidine improves surv

122 Postoperative HAI oxaliplatin combined with systemic chemotherapy after cu

123 A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal ant

124 ned, most of whom received fluorouracil- and oxaliplatin-containing chemotherapy regimens.

125 Patients who had received adjuvant oxaliplatin could receive irinotecan 180 mg/m(2) intrave

126 We report the first large series of oxaliplatin desensitizations.

127 ated an additional dose of 458 +/- 207 mg/m2 oxaliplatin despite preexisting neuropathy.

128 ceiving the platinum-based chemotherapy drug oxaliplatin develop peripheral neurotoxicity.

129 Patients with stage II disease receiving oxaliplatin did not exhibit a significant reduction in r

130 Adding oxaliplatin did not improve surgical outcomes but added

131 The beneficial effect of chemotherapy and oxaliplatin did not seem solely attributable to confound

132 ng of outcomes between treatment groups (ie, oxaliplatin did not simply postpone recurrence or death

133 cer drugs, such as 5-fluorouracil (5-FU) and oxaliplatin, exert such effects, their combination as em

134 Patients treated with oxaliplatin experienced significantly more grade 3 or 4

135 X (leucovorin, fluorouracil, irinotecan, and oxaliplatin; favorable comorbidity profile) or gemcitabi

136 lexes, including cisplatin, carboplatin, and oxaliplatin, finding that DMSO reacted with the complexe

137 the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as c

138 e addition of cetuximab to standard adjuvant oxaliplatin, fluorouracil, and leucovorin chemotherapy (

139 e MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Trea

140 (leucovorin), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), restrict their full utility in

141 with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown.

142 to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or FOLFOX plus cetuximab, 1,968 par

143 th combination leucovorin, fluorouracil, and oxaliplatin (FOLFOX)-based adjuvant chemotherapy is cont

144 es to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with

145 ive infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevacizumab with selective rather t

146 ompared with those given 5-fluorouracil plus oxaliplatin (FOLFOX; cycle 1 mean grade nausea 1.1 [SD 1

147 cil plus leucovorin (LV5FU2) and LV5FU2 plus oxaliplatin (FOLFOX4) arms were 67.1% versus 71.7% (haza

148 treated with a fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) regimen.

149 bevacizumab to fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) for the adjuvant treatment of pati

150 rinotecan+folinic acid] than to FOLFOX (5-FU+oxaliplatin+folinic acid), not only between isogenic tum

151 fluorouracil (FU) and oxaliplatin using the oxaliplatin, folinic acid, and FU (OFF) regimen.

152 Chemotherapy was FOLFOX (folinic acid and oxaliplatin followed by bolus and infused fluorouracil).

153 ith ATP release and strongly synergized with oxaliplatin for the exposure of the three hallmarks of i

154 r fluoropyrimidine treatment with or without oxaliplatin from 60 centres in the UK.

155 However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carbopla

156 leucovorin and fluorouracil with or without oxaliplatin groups.

157 OX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX

158 leucovorin and fluorouracil with or without oxaliplatin has not been directly compared; therefore, w

159 imidines and more recently combinations with oxaliplatin-has reduced the risk of tumor recurrence and

160 antly, two compounds, 14Ru and 18Ru, matched oxaliplatin IC50 (0.45 muM), the standard metallodrug us

161 a critical mediator of CIPN by bortezomib or oxaliplatin in a mouse model system.

162 ggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR],

163 ied to map the penetration and metabolism of oxaliplatin in hyperthermic intraperitoneal chemotherapy

164 mly assigned to fluorouracil (FU) or FU plus oxaliplatin in National Surgical Adjuvant Breast and Bow

165 nd FANCD2 monoubiquitinations are induced by oxaliplatin in parental HCT116 cells.

166 ar overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer.

167 polymer (NCP) core-shell nanoparticles carry oxaliplatin in the core and the photosensitizer pyropheo

168 covorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally advanced pancreati

169 combination with DNA damaging agents (MMC or oxaliplatin) in PDA cell lines that are either DNA repai

170 X4 (infusional fluorouracil, leucovorin, and oxaliplatin) in study 20050203, FOLFIRI (fluorouracil, l

171 n P = .48); accordingly, absolute benefit of oxaliplatin increased with higher scores, most notably i

172 ium/magnesium did not substantially decrease oxaliplatin-induced acute neuropathy.

173 shed OCT2 activity, significantly mitigating oxaliplatin-induced acute sensory neuropathy.

174 din-7-amides were effective in counteracting oxaliplatin-induced apoptosis in rat astrocyte cell cult

175 rred resistance to 5-fluorouracil (5-FU)- or oxaliplatin-induced apoptosis in vitro and reduced the e

176 Accordingly, Egr1 downregulation reduced oxaliplatin-induced apoptosis, whereas E2F1 downregulati

177 inesterase inhibitor, prevented and reversed oxaliplatin-induced cold and mechanical allodynia as wel

178 ssociated with increased DNA platination and oxaliplatin-induced cytotoxicity.

179 e pIC using oxotremorine completely reversed oxaliplatin-induced mechanical allodynia.

180 Oxaliplatin-induced mechanical hyperalgesia was reduced

181 e G-protein coupled receptor G2A (GPR132) in oxaliplatin-induced neuropathic pain in mice.

182 icin-induced neurogenic pain, and notably in oxaliplatin-induced neuropathic pain in mice.

183 h 3 by different paradigms in a rat model of oxaliplatin-induced neuropathic pain, showed the better

184 enrolled 23 cancer patients with grade >/= 2 oxaliplatin-induced neuropathy in a phase II study, with

185 that mangafodipir can prevent and/or relieve oxaliplatin-induced neuropathy in cancer patients.

186 Given that the clinical course of oxaliplatin-induced neuropathy is not well defined, the

187 Acute oxaliplatin-induced neuropathy symptoms do not always co

188 nvolved in pain processing in a rat model of oxaliplatin-induced neuropathy using HRMAS (1)H-NMR spec

189 e profile being able to fully counteract the oxaliplatin-induced neuropathy.

190 t using calcium/magnesium to protect against oxaliplatin-induced neurotoxicity.

191 gnesium have been extensively used to reduce oxaliplatin-induced neurotoxicity.

192 which are established tests to assess acute oxaliplatin-induced neurotoxicity.

193 ng G2A may be a promising approach to reduce oxaliplatin-induced TRPV1-sensitization and the hyperexc

194 However, only the UV and oxaliplatin-induced upregulation of p73 mediated by the

195 hemotherapy was modified FOLFOX6 (85 mg/m(2) oxaliplatin infusion over 2 h, 200 mg leucovorin, and 40

196 modified de Gramont chemotherapy; 85 mg/m(2) oxaliplatin infusion over 2 h, L-leucovorin 175 mg or D,

197 rable comorbidity profile; fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal irinotecan sho

198 ly nausea for patients given irinotecan plus oxaliplatin (IROX) compared with those given 5-fluoroura

199 Oxaliplatin is an integral component of colorectal cance

200 Open high-pressure HIPEC with oxaliplatin is feasible in the pig.

201 in germ cell, breast and lung malignancies, oxaliplatin is instead used almost exclusively to treat

202 anglia cells within the nervous system where oxaliplatin is known to accumulate.

203 Oxaliplatin is successfully used in systemic cancer ther

204 Rather, oxaliplatin kills cells by inducing ribosome biogenesis

205 Infusion of the chemotherapeutic agent oxaliplatin leads to an acute and a chronic form of peri

206 , irinotecan plus cisplatin (IC), or FOLFOX (oxaliplatin, leucovorin, and bolus and infusional fluoro

207 modified FOLFIRINOX chemotherapy (comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil) i

208 ved infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) combined with bevacizumab.

209 combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leu

210 ostaglandin E2 and the chemotherapeutic drug oxaliplatin, modeling the inherent mechanisms underlying

211 In FOXFIRE, FOLFOX chemotherapy was OxMdG (oxaliplatin modified de Gramont chemotherapy; 85 mg/m(2)

212 Additionally, patients who received oxaliplatin more often reported tingling (29% v 8%; P =

213 Melphalan (n = 69) (CRC = 32, non-CRC = 37), Oxaliplatin (n = 10) (CRC), or Oxaliplatin + 5FU (n = 12

214 ropathy, whereas a common symptom of chronic oxaliplatin neuropathy is pain.

215 l dysesthesias are rarely reported for acute oxaliplatin neuropathy, whereas a common symptom of chro

216 n (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epide

217 juvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08CB (North Central Cancer Treatm

218 enium complexes as compared to cisplatin and oxaliplatin, on both cisplatin-sensitive and cisplatin r

219 cell lines displaying acquired resistance to oxaliplatin or cisplatin.

220 owth when compared to NCP particles carrying oxaliplatin or GMP alone.

221 treatment, including a fluoropyrimidine and oxaliplatin or irinotecan.

222 erapy (FOLFOX: leucovorin, fluorouracil, and oxaliplatin) or FOLFOX plus single treatment SIRT concur

223 es for CRC patients using 5FU + Oxaliplatin, Oxaliplatin, or Melphalan were 83.3%, 66.7%, and 60.9%,

224 622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and corre

225 ffect of anticancer drugs doxorubicin (DOX), oxaliplatin (OX) as well as OX-loaded liposomes, develop

226 y of cancer drugs such as cisplatin (Cp) and oxaliplatin (Ox), which covalently bind to DNA to form d

227 of the ICD-inducing chemotherapeutic agent, oxaliplatin (OX).

228 Modification of oxaliplatin (OXA) into a lipophilic Pt(IV) complex [Pt(D

229 Resistance to oxaliplatin (OXA) is a complex process affecting the out

230 Oxaliplatin (OXA) is a valuable and largely used cancer

231 Response rates for CRC patients using 5FU + Oxaliplatin, Oxaliplatin, or Melphalan were 83.3%, 66.7%

232 These data add to the existing evidence that oxaliplatin plus capecitabine or leucovorin and fluorour

233 d 2010, palliative combination chemotherapy (oxaliplatin plus capecitabine) after the diagnosis of ne

234 platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new

235 by centre, WHO performance status, previous oxaliplatin, previous bevacizumab, previous dose modific

236 was utilized to develop a novel platinum(IV) oxaliplatin prodrug and incorporate it into a three-drug

237 +/- 3 wt% cisplatin prodrug and 45 +/- 5 wt% oxaliplatin prodrug.

238 Combination therapy with oxaliplatin provided consistently improved outcomes with

239 Oxaliplatin-specific IgE was determined in oxaliplatin-reactive patients (who underwent DPT regardl

240 and oxaliplatin-ST in the largest series of oxaliplatin-reactive patients reported to date (74 oxali

241 latin-reactive patients reported to date (74 oxaliplatin-reactive patients).

242 In 10 oxaliplatin-reactive patients, 38 desensitizations were

243 Specific IgE was determined in oxaliplatin-reactive patients.

244 sly over 30 min with fluorouracil instead of oxaliplatin (regimen three).

245 ely test whether calcium/magnesium decreases oxaliplatin-related neurotoxicity.

246 ains the distinct clinical implementation of oxaliplatin relative to cisplatin, and it might enable m

247 nticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular translational scienc

248 ing an isogenic HCT116 colon cancer model of oxaliplatin resistance, we further show that gammaH2AX a

249 r cells with innate or acquired cisplatin or oxaliplatin resistance.

250 nd FANCD2 are constitutively up-regulated in oxaliplatin-resistant HCT116 (HCT116-OxR) cells and that

251 /- 3.9 h for the NCPs carrying cisplatin and oxaliplatin, respectively.

252 eoplastic and biological agents (paclitaxel, oxaliplatin, rituximab, infliximab, irinotecan, and othe

253 Oxaliplatin, satraplatin, and picoplatin are cisplatin a

254 Because oxaliplatin, satraplatin, and picoplatin contain bulkier

255 amined multiple responses of cancer cells to oxaliplatin, satraplatin, or picoplatin treatment under

256 Addition of oxaliplatin significantly reduced the risk of recurrence

257 Sensitivity for oxaliplatin-specific IgE (0.35 UI/l cutoff point) was 34

258 ols; consequently, quality data are shown on oxaliplatin-specific IgE and oxaliplatin-ST in the large

259 Oxaliplatin-specific IgE determination could be helpful.

260 ve patients (who underwent DPT regardless of oxaliplatin-specific IgE results).

261 Sensitivity for oxaliplatin-specific IgE was 38% (0.35UI/l cutoff point)

262 Oxaliplatin-specific IgE was determined in oxaliplatin-r

263 dous drugs exposure risks) and to assess the oxaliplatin-specific immunoglobulin E (IgE) as a novel d

264 logy Criteria for Adverse Events scale or an oxaliplatin-specific neuropathy scale.

265 ta are shown on oxaliplatin-specific IgE and oxaliplatin-ST in the largest series of oxaliplatin-reac

266 injected with a cumulative dose of 30 mg/kg oxaliplatin (sufficient to induce neurotoxicity) or dext

267 Unlike cisplatin and oxaliplatin, the efficacies of which are influenced by P

268 rently randomized to FU + LV with or without oxaliplatin; the latter analyses supported time-dependen

269 These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy i

270 ed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting

271 hown to be significantly more cytotoxic than oxaliplatin to HCT116 cells, triggering higher levels of

272 cts synergistically with EGFR inhibitors and oxaliplatin to inhibit cell proliferation and induce apo

273 Oxaliplatin treated animals had comparable transport at

274 the sciatic nerve and dorsal root ganglia of oxaliplatin treated mice.

275 s modeled over 6 years post treatment in all oxaliplatin-treated patients and patients concurrently r

276 nist, methoctramine, within the pIC, in both oxaliplatin-treated rats and spared nerve injury rats.

277 ch was confirmed by Western blot analysis in oxaliplatin-treated rats and the spared nerve injury mod

278 a lower level of acetylcholine in the pIC of oxaliplatin-treated rats, which was significantly increa

279 cancer, allows CTL-dependent eradication of oxaliplatin-treated tumours.

280 ed the chemosensitivity of HCC cells towards oxaliplatin treatment by way of a collective result of s

281 In wild-type mice, oxaliplatin treatment produced cold allodynia that could

282 ced pain, after paclitaxel, other taxane, or oxaliplatin treatment.

283 decreased mechanical hypersensitivity after oxaliplatin treatment.

284 se prostate cancer models were refractory to oxaliplatin unless genetically or pharmacologically depl

285 We show that oxaliplatin, unlike cisplatin and carboplatin, does not

286 nefit with second-line fluorouracil (FU) and oxaliplatin using the oxaliplatin, folinic acid, and FU

287 Adjuvant capecitabine with or without oxaliplatin versus leucovorin and fluorouracil with or w

288 X6; infusional fluorouracil, leucovorin, and oxaliplatin) versus infusional FU/leucovorin (LV) in thi

289 ed in three phase 3 colon cancer trials when oxaliplatin was added to fluoropyrimidines, although the

290 Cellular uptake of oxaliplatin was increased by 16- to 35-fold in cells ove

291 Relative benefit of oxaliplatin was similar across the range of Recurrence S

292 Oxaliplatin was subsequently used in 55.9% (arm A) and 5

293 , sensitizes the cells to 5-fluorouracil and oxaliplatin.We investigated whether HSP110 T(17) could b

294 y with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) were randomly assigned to intravenous calci

295 ers (OCTs), uptake carriers of metformin and oxaliplatin, were inhibited by several clinically used T

296 , were quickly reduced to their active form, oxaliplatin, when co-incubated with a macrocycle metallo

297 Administration of bortezomib or oxaliplatin, which also elicits TRPA1-dependent hypersen

298 se B cells modulate the response to low-dose oxaliplatin, which promotes tumour-directed CTL activati

299 fectiveness of fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab in the first-lin

300 d toxicity was observed with the addition of oxaliplatin, with grade 3/4 adverse events occurring in